Together with blood/sputum eosinophil count, high FeNO may be a biomarker for the late-onset severe asthma phenotype. Clinical characteristics of this phenotype may include chronic rhinosinusitis with nasal polyps and/or steroid refractoriness.
The AERD phenotype is also typically severe from onset, with frequent exacerbations. In such patients, helpful biomarkers for identification include blood/sputum eosinophil count and urinary leukotriene E4 (LTE4).
Serum IL-6 is a biomarker that may be seen in the obese asthma phenotype.
Induced sputum neutrophil count is another biomarker than can help to identify asthma phenotypes. Recently, association of neutrophilic airway inflammation with severe asthma has been shown in the context of non–type 2 inflammation, which may or may not be accompanied by type 2 inflammation and airway eosinophils.
For additional information, refer to the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention.
Learn more about combination therapy in the management of patients with severe asthma.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Severe Asthma Phenotypes - Medscape - Apr 05, 2021.